Fatty liver disease: 'Pruritus' in the hands and feet may be worse in the 'late-evening'
Fatty liver disease symptoms are scarce in the initial stages, but they can quickly become unbearable once they emerge. (Source: Daily Express - Health)
Source: Daily Express - Health - January 21, 2023 Category: Consumer Health News Source Type: news
'Tiny red lines' on the skin could signal the most advanced stage of fatty liver disease
These markings can appear on skin above the waist and may indicate the need for medical help. (Source: Daily Express - Health)
Source: Daily Express - Health - January 19, 2023 Category: Consumer Health News Source Type: news
Association of NAFLD Between Parents and Adolescent Children Association of NAFLD Between Parents and Adolescent Children
This study found that adolescent children with a parent with NAFLD were at increased risk of NAFLD.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 19, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Investor Update - January 19, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Media News - January 19, 2023 Category: Pharmaceuticals Source Type: news
